AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib ...

AstraZeneca Pharma India has surrendered marketing authorization for Olaparib (Lynparza) in India due to commercial reasons. The drug is indicated for metastatic castration-resistant prostate cancer.

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) for indication in combination with ...

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast cancer – the first drug in the class to show that in a clinical trial.

We, like so many others, have been forced to take steps to extend our cash runway,” said Tango’s CEO, citing “extremely ...

evaluating pocenbrodib alone and with other drug combinations. The first patent has been dosed in the phase 1b/2a clinical trial P300-02-001, which is evaluating pocenbrodib alone, and in combination ...

and earns alliance revenues from three other drugs - Lynparza, Lenvima, and Reblozyl - ~$2.7bn in 2024. Merck’s vaccines division earned $12.85bn revenues in 2024, or ~22% of all revenues ...

The University of Sheffield and Yorkshire Cancer Research are pioneering 10 world-leading research studies that aim to ...